drugset / Trial / NCT01452217

Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers

NCT01452217

Phase 1 Completed 12 enrolled University of Nottingham
Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Alterations in pancreatic blood have been implicated in pancreatic inflammation and pain. Several modalities have been used to assess pancreatic blood flow although some of these methods are invasive, use ionising radiation or intravenous contrast media. This is the first study to utilise non-invasive magnetic resonance imaging to quantify flow within arteries supplying the pancreas and pancreatic perfusion is response to secretin stimulation.

Timeline

Start
2010-09
Primary completion
2011-09
Completion
2011-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Secretin Other / unclassified 1 iu/kg Intravenous

Indications